AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3316518 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine added to metoclopramide and dexamethasone
Number of subjects: 31
Study 3316518 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide and dexamethasone alone
Number of subjects: 31
Study 31763732 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel combination powder (CP) - HEMOBLAST Bellows; Biom'up, France
Number of subjects: 105
Study 31763732 — intervention group
Group type: COMPARATOR
Intervention: Control hemostatic matrix (HM) - FLOSEAL Hemostatic Matrix; Baxter Healthcare Corporation
Number of subjects: 105
Study 30224318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 807
Study 30224318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 100 mg twice daily
Number of subjects: 807
Study 30224318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 807
Study 28611391 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucosinolate diet for 14 days prior to surgery
Number of subjects: 40
Study 28611391 — intervention group
Group type: COMPARATOR
Intervention: Low glucosinolate diet for 14 days prior to surgery
Number of subjects: 40
Study 26561294 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy at high-enrolling sites
Number of subjects: 0
Study 26561294 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy at low-enrolling sites
Number of subjects: 0
Study 26561294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups at high-enrolling sites
Number of subjects: 0
Study 26561294 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment groups at low-enrolling sites
Number of subjects: 0
Study 23009249 — intervention group
Group type: EXPERIMENTAL
Intervention: i-SCAN
Number of subjects: 514
Study 23009249 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 514
Study 21781409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 143
Study 21781409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 19309495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% taurolidine/2,500 IU heparin (TRD)
Number of subjects: 120
Study 19309495 — intervention group
Group type: COMPARATOR
Intervention: 0.25% povidone-iodine (control)
Number of subjects: 120
Study 19309495 — intervention group
Group type: COMPARATOR
Intervention: TRD and Control
Number of subjects: 120
Study 16394963 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training plus education (WT + ED)
Number of subjects: 64
Study 16394963 — intervention group
Group type: COMPARATOR
Intervention: Weight training (WT)
Number of subjects: 64
Study 14991469 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg via gastric tube
Number of subjects: 30
Study 14991469 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30
Study 14991469 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 30
Study 11682375 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil continuous infusion
Number of subjects: 68
Study 9177060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disulfiram
Number of subjects: 24
Study 9177060 — intervention group
Group type: COMPARATOR
Intervention: Implanted disulfiram
Number of subjects: 24
Study 8195550 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day food record
Number of subjects: 58
Study 8195550 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 58
Study 8195550 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day food frequency
Number of subjects: 58
Study 2895829 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (above 250 micrograms or 50 international units per week)
Number of subjects: 70
Study 2895829 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol (positive control)
Number of subjects: 70
Study 30912285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone salts (0.3 g β‐OHB per kg)
Number of subjects: 28
Study 30912285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester (0.482 g β‐OHB per kg)
Number of subjects: 28
Study 30912285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29049251 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 0.5 mg/kg
Number of subjects: 16
Study 29049251 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (control group)
Number of subjects: 16
Study 25670026 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 27
Study 25670026 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 27
Study 24368165 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT) - mentally simulated the sequence of events expected to occur on the second day, including the PM task.
Number of subjects: 0
Study 24368165 — intervention group
Group type: COMPARATOR
Intervention: Control tasks - participants performed tasks that did not involve mentally simulating future events.
Number of subjects: 0
Study 23168159 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic splint placed in the middle meatus for 2 weeks
Number of subjects: 42
Study 23168159 — intervention group
Group type: COMPARATOR
Intervention: Nonsplinted sides
Number of subjects: 42
Study 23168159 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic splint
Number of subjects: 42
Study 23168159 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic splint and nonsplinted sides
Number of subjects: 42
Study 20329604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailing Capsule (BLC)
Number of subjects: 67
Study 20329604 — intervention group
Group type: COMPARATOR
Intervention: Control group (mycophenolate mofetil (MMF) plus cyclosporine A (CsA), or tacrolimus (FK506) plus prednisone (Pred))
Number of subjects: 67
Study 17877513 — intervention group
Group type: EXPERIMENTAL
Intervention: EBAL (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., amoxicillin 1 g b.d. and levofloxacin 500 mg b.d.)
Number of subjects: 102
Study 17877513 — intervention group
Group type: COMPARATOR
Intervention: EBMT (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., metronidazole 400 mg t.d.s. and tetracycline 500 mg q.d.s.)
Number of subjects: 102
Study 17877513 — intervention group
Group type: EXPERIMENTAL
Intervention: EBAL
Number of subjects: 102
Study 17877513 — intervention group
Group type: COMPARATOR
Intervention: EBMT
Number of subjects: 102
Study 15617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimate (MLE) based on normality assumptions
Number of subjects: 0
Study 15617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-extrapolation estimate (SIMEX)
Number of subjects: 0
Study 15617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude NNT estimation
Number of subjects: 0
Study 15617950 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical data from a randomized study of cholesterol-lowering therapy
Number of subjects: 0
Study 12693435 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on personal responsibility
Number of subjects: 213
Study 12693435 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on dangerousness
Number of subjects: 213
Study 12693435 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a person with serious mental illness discussing personal responsibility
Number of subjects: 213
Study 12693435 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a person with serious mental illness discussing dangerousness
Number of subjects: 213
Study 12693435 — intervention group
Group type: COMPARATOR
Intervention: No change (control group)
Number of subjects: 213
Study 9721941 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg)
Number of subjects: 26
Study 9721941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7711623 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit facilitator intervention (n = 1585)
Number of subjects: 3373
Study 7711623 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 1563)
Number of subjects: 3373
Study 2653325 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily for 2 months)
Number of subjects: 16
Study 2653325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 408607 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron daily
Number of subjects: 128
Study 408607 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron, 0.44 mg folic acid and 0.66 mg vitamin B12 daily
Number of subjects: 128
Study 408607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (37 pregnant women)
Number of subjects: 128
Study 408607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined iron preparation
Number of subjects: 128
Study 31359804 — intervention group
Group type: EXPERIMENTAL
Intervention: S-amlodipine 5 mg for 10 days followed by S-amlodipine 5 mg plus bisoprolol 5 mg for 7 days
Number of subjects: 32
Study 31359804 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol 5 mg for 7 days followed by S-amlodipine 5 mg plus bisoprolol 5 mg for 10 days
Number of subjects: 32
Study 31359804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups monitored for adverse events
Number of subjects: 32
Study 28926669 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy‐considered diabetes self‐management program
Number of subjects: 51
Study 26632106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary use
Number of subjects: 127
Study 26632106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary removal during sex
Number of subjects: 127
Study 23845398 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week gym- and home-based exercise program
Number of subjects: 20
Study 21667769 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit handwriting program (two weekly sessions of 45 min. over six weeks)
Number of subjects: 23
Study 21667769 — intervention group
Group type: COMPARATOR
Intervention: Regular handwriting program (one weekly session)
Number of subjects: 23
Study 20128337 — intervention group
Group type: EXPERIMENTAL
Intervention: A Matter of Balance program (12-week small-group based balance program)
Number of subjects: 23
Study 20128337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 16641143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (ergocalciferol 2.5 mg every 3 months, equivalent to a daily dose of 1,100 IU)
Number of subjects: 3717
Study 16641143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 3717
Study 15575123 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits by public health nurses over 18 months (mean home visits=4.3)
Number of subjects: 119
Study 15575123 — intervention group
Group type: COMPARATOR
Intervention: Usual primary and community care
Number of subjects: 119
Study 11745967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified orthodromic inching test (SOIT)
Number of subjects: 50
Study 11745967 — intervention group
Group type: COMPARATOR
Intervention: Orthodromic median‐ulnar latency difference of the 4th digit
Number of subjects: 50
Study 9416381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate liquid containing Veegum (Pepto‐Bismol)
Number of subjects: 11
Study 9416381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate formulation without Veegum
Number of subjects: 11
Study 9416381 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline hydrochloride with water (reference treatment)
Number of subjects: 11
Study 8486198 — intervention group
Group type: EXPERIMENTAL
Intervention: CC/tamoxifen (50 mg CC and 20 mg tamoxifen during cycle days 5 to 9)
Number of subjects: 20
Study 8486198 — intervention group
Group type: COMPARATOR
Intervention: CC (100 mg CC during cycle days 5 to 9)
Number of subjects: 20
Study 3511693 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10
Study 3511693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 10
Study 29517265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring the prime during the study phase
Number of subjects: 0
Study 29517265 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention task on prime presentation
Number of subjects: 0
Study 29517265 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming each prime
Number of subjects: 0
Study 29517265 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting the vowels in each prime
Number of subjects: 0
Study 29517265 — intervention group
Group type: EXPERIMENTAL
Intervention: Making a semantic discrimination for each prime
Number of subjects: 0
Study 29517265 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory assessment for not-repeated primes
Number of subjects: 0
Study 26690310 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 overexpression
Number of subjects: 3256
Study 26690310 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 amplification by FISH
Number of subjects: 3256
Study 26690310 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted therapy
Number of subjects: 3256
Study 24486117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Number of subjects: 78
Study 24486117 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 78
Study 22065400 — intervention group
Group type: COMPARATOR
Intervention: bosutinib 500 mg with food (therapeutic)
Number of subjects: 60
Study 22065400 — intervention group
Group type: COMPARATOR
Intervention: bosutinib 500 mg plus ketoconazole (supratherapeutic)
Number of subjects: 60
Study 22065400 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 22065400 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin
Number of subjects: 60
Study 16020405 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/day (increased to 160 mg as tolerated)
Number of subjects: 42
Study 16020405 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg/day (increased to 10 mg as tolerated)
Number of subjects: 42
Study 11835026 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC adjudicated MIs
Number of subjects: 5225
Study 11835026 — intervention group
Group type: COMPARATOR
Intervention: Investigator assessments
Number of subjects: 5225
Study 11835026 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement with CEC assessments
Number of subjects: 5225
Study 11835026 — intervention group
Group type: COMPARATOR
Intervention: Disagreements confirmed
Number of subjects: 5225
Study 9857885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamifiban (GP IIb/IIIa inhibitor)
Number of subjects: 0
Study 9857885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7832332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with nitrous oxide (group SN)
Number of subjects: 120
Study 7832332 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane with nitrous oxide (group HN)
Number of subjects: 120
Study 7832332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 120
Study 7832332 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (group HN)
Number of subjects: 120
Study 2212410 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrimp-specific IgG2
Number of subjects: 51
Study 2212410 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrimp-specific IgG4
Number of subjects: 51
Study 2212410 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC (double-blind, placebo-controlled food challenge)
Number of subjects: 51
Study 574523 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of fenoterol (beta 2‐receptor stimulator)
Number of subjects: 18
Study 574523 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of Freons
Number of subjects: 18
Study 31371434 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred cord clamping (≥2 min)
Number of subjects: 276
Study 31371434 — intervention group
Group type: COMPARATOR
Intervention: Immediate clamping (≤20 s)
Number of subjects: 276
Study 30245732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantra Meditation (MM)
Number of subjects: 22
Study 30245732 — intervention group
Group type: COMPARATOR
Intervention: Music Listening (ML)
Number of subjects: 22
Study 27763958 — intervention group
Group type: EXPERIMENTAL
Intervention: InterTAN intramedullary device (n = 123)
Number of subjects: 249
Study 27763958 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw (n = 126)
Number of subjects: 249
Study 26264767 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant high tibial osteotomy (HTO) and anterior cruciate ligament (ACL) reconstruction
Number of subjects: 33
Study 23756346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (750mg docosahexaenoic plus eicosapentaenoic acids, and 60mg gamma linolenic acid/school day) during Phase 1
Number of subjects: 409
Study 23756346 — intervention group
Group type: COMPARATOR
Intervention: Placebo during Phase 1
Number of subjects: 409
Study 23756346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (after crossover in Phase 2)
Number of subjects: 409
Study 20087760 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 pulses ATP
Number of subjects: 925
Study 20087760 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 pulses ATP
Number of subjects: 925
Study 18856250 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed oral care (toothbrushing every 8 hours)
Number of subjects: 24
Study 18856250 — intervention group
Group type: COMPARATOR
Intervention: Usual oral care (control group)
Number of subjects: 24
Study 16243588 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemene injections
Number of subjects: 127
Study 14600700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound/doppler examination
Number of subjects: 20
Study 14600700 — intervention group
Group type: COMPARATOR
Intervention: Periapical radiographs
Number of subjects: 20
Study 11111130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g of n-3 PUFA/day as fish oil capsule
Number of subjects: 25
Study 11111130 — intervention group
Group type: COMPARATOR
Intervention: 0.9 g of n-3 PUFA/day from enriched foods
Number of subjects: 25
Study 8686411 — intervention group
Group type: EXPERIMENTAL
Intervention: High potency pancreatin (9 g, 3 g x 3 times) for approximately 1 month
Number of subjects: 12
Study 1422647 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleotrain
Number of subjects: 220
Study 3900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin, 20 mg/kg, once daily for four days
Number of subjects: 492
Study 3900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin, 10 mg/kg, twice a day for four days
Number of subjects: 492
Study 3900905 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily for four days
Number of subjects: 492
Study 3900905 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug regimens (including placebo)
Number of subjects: 492
Study 3900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticapsular antibody concentration measurement
Number of subjects: 492
Study 30935617 — intervention group
Group type: COMPARATOR
Intervention: K3XF rotary system with continuous rotary movement
Number of subjects: 45
Study 30935617 — intervention group
Group type: EXPERIMENTAL
Intervention: K3XF rotary system with adaptive movement
Number of subjects: 45
Study 30935617 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted File adaptive file with adaptive movement
Number of subjects: 45
Study 29750971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 IU)
Number of subjects: 0
Study 29750971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 0
Study 29750971 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (1 IU)
Number of subjects: 0
Study 29750971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26808973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 173
Study 26808973 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 173
Study 24839144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) 200 mg/d
Number of subjects: 50
Study 24839144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24839144 — intervention group
Group type: COMPARATOR
Intervention: Healthy term neonates
Number of subjects: 50
Study 21875758 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.1%
Number of subjects: 16
Study 21875758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20590588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (0.2 mg x kg(‐1)) alone
Number of subjects: 10
Study 20590588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone after inhibition of CYP2D6 (with quinidine)
Number of subjects: 10
Study 20590588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone after inhibition of CYP3A (with ketoconazole)
Number of subjects: 10
Study 20590588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18657487 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based GP-mediated intervention
Number of subjects: 9685
Study 18657487 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 9685
Study 15795705 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg losartan
Number of subjects: 33
Study 15795705 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 33
Study 15795705 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 33
Study 11850708 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus ursodiol
Number of subjects: 165
Study 11850708 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 165
Study 10614959 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (Filgrastim; Roche, Switzerland)
Number of subjects: 30
Study 10614959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7807033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 25